Published in Ann Intern Med on January 26, 2016
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease (REVEAL) | NCT00462917
Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO (PCD=OOALZ) | NCT02835716
Genomics: Prediction, Prevention, Priorities, and Punnett. Ann Intern Med (2016) 0.75
Disclosing Genetic Risk for Coronary Heart Disease: Attitudes Toward Personal Information in Health Records. Am J Prev Med (2017) 0.75
Does a medical history of hypertension influence disclosing genetic testing results of the risk for salt-sensitive hypertension, in primary care? Int J Gen Med (2016) 0.75
Disclosing genetic risk of Alzheimer's disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Educ Couns (2016) 0.75
A randomized trial Examining The Impact Of Communicating Genetic And Lifestyle Risks For Obesity. Obesity (Silver Spring) (2016) 0.75
An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol (1988) 26.07
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med (2013) 22.73
Impact of Event Scale: a measure of subjective stress. Psychosom Med (1979) 21.82
The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry (1987) 19.45
Trials to assess equivalence: the importance of rigorous methods. BMJ (1996) 9.29
Molecular findings among patients referred for clinical whole-exome sequencing. JAMA (2014) 6.46
Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med (2009) 6.43
Diagnostic clinical genome and exome sequencing. N Engl J Med (2014) 5.55
Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA (2007) 4.03
Point-counterpoint. Patient autonomy and incidental findings in clinical genomics. Science (2013) 3.86
Abundant pleiotropy in human complex diseases and traits. Am J Hum Genet (2011) 3.60
Sample sizes for clinical trials with normal data. Stat Med (2004) 3.47
Recommendations for returning genomic incidental findings? We need to talk! Genet Med (2013) 3.23
The Rapid Assessment of Physical Activity (RAPA) among older adults. Prev Chronic Dis (2006) 3.12
Anticipate and communicate: Ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues). Am J Epidemiol (2014) 3.10
A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med (2008) 3.06
Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med (2004) 2.82
Point-counterpoint. Ethics and genomic incidental findings. Science (2013) 2.73
Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med (2004) 2.56
Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele? Ann Hum Genet (1999) 2.40
Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord (2008) 2.30
Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol (2005) 2.03
ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med (2014) 1.95
Understanding equivalence and noninferiority testing. J Gen Intern Med (2010) 1.91
Attitudes of genetics professionals toward the return of incidental results from exome and whole-genome sequencing. Am J Hum Genet (2014) 1.52
Reporting genomic sequencing results to ordering clinicians: incidental, but not exceptional. JAMA (2013) 1.48
Ancillary risk information and pharmacogenetic tests: social and policy implications. Pharmacogenomics J (2007) 1.34
Outcome measurement in clinical genetics services: a systematic review of validated measures. Value Health (2008) 1.32
Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr (2010) 1.25
Returning pleiotropic results from genetic testing to patients and research participants. JAMA (2014) 1.10
The question not asked: the challenge of pleiotropic genetic tests. Kennedy Inst Ethics J (1998) 1.09
Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genet Med (2008) 1.08
Incidental findings in genetic research and clinical diagnostic tests: a systematic review. Am J Med Genet A (2012) 1.07
Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease. Genet Med (2012) 0.95
Dementia update 2005. Alzheimer Dis Assoc Disord (2005) 0.94
The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet (2014) 0.90
A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. Alzheimers Dement (2014) 0.87
The hidden harm behind the return of results from personal genome services: a need for rigorous and responsible evaluation. Genet Med (2014) 0.83
Integration of genomics into medical practice. Discov Med (2013) 0.83
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet Med (2012) 9.65
Broad Consent for Research With Biological Samples: Workshop Conclusions. Am J Bioeth (2015) 8.99
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med (2009) 6.43
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med (2015) 6.28
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 5.64
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
Diagnostic clinical genome and exome sequencing. N Engl J Med (2014) 5.55
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet (2009) 5.32
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ (2013) 5.08
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet (2009) 4.71
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med (2004) 4.34
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Genomewide linkage analysis of body mass index across 28 years of the Framingham Heart Study. Am J Hum Genet (2002) 4.07
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci (2004) 3.73
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
Bare metal stent restenosis is not a benign clinical entity. Am Heart J (2006) 3.39
Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation (2011) 3.30
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Recommendations for returning genomic incidental findings? We need to talk! Genet Med (2013) 3.23
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. PLoS Genet (2009) 3.18
Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA (2002) 3.16
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation (2012) 3.14
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
The landscape of recombination in African Americans. Nature (2011) 3.06
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05
Genetic associations with valvular calcification and aortic stenosis. N Engl J Med (2013) 3.02
Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol (2013) 2.99
Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med Genet (2007) 2.93
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet (2010) 2.91
Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol (2010) 2.83
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med (2004) 2.82
Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J (2005) 2.80
Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med (2009) 2.80
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
Disclosing pathogenic genetic variants to research participants: quantifying an emerging ethical responsibility. Genome Res (2012) 2.76
CPAP versus oxygen in obstructive sleep apnea. N Engl J Med (2014) 2.75
Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet (2011) 2.73
Point-counterpoint. Ethics and genomic incidental findings. Science (2013) 2.73
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67
Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium. PLoS One (2013) 2.65
Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med (2012) 2.64
Whole-genome sequence-based analysis of high-density lipoprotein cholesterol. Nat Genet (2013) 2.62
Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA (2013) 2.62
Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol (2005) 2.61
A 100K genome-wide association scan for diabetes and related traits in the Framingham Heart Study: replication and integration with other genome-wide datasets. Diabetes (2007) 2.60
Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA (2013) 2.58
Association of JAG1 with bone mineral density and osteoporotic fractures: a genome-wide association study and follow-up replication studies. Am J Hum Genet (2010) 2.57
Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol (2003) 2.56